{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:29:44Z","timestamp":1792225784118,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T00:00:00Z","timestamp":1196726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deferasirox (Exjade\u00ae, ICL670) is a once\u2010daily, oral iron chelation agent that is now widely available for the treatment of transfusional hemosiderosis in adult and pediatric patients aged \u22652 years of age. Clinical evaluation has established the efficacy and safety of this novel agent in patients with a variety of chronic anemias. Deferasirox represents a significant advance in the treatment of iron overload, as the availability of an effective oral therapy has the potential to relieve many patients from the burden of frequent parenteral therapy with the previous reference standard iron chelator, deferoxamine. The most common drug\u2010related adverse events seen in the core registration trials were gastrointestinal disturbances, rash, mild and nonprogressive increases in serum creatinine levels, and elevations in liver enzyme levels. Most events were transient, mild\u2010to\u2010moderate in severity, and easily managed without discontinuation of treatment. As with any new agent, it is important that treating physicians are familiar with the adverse event profile of deferasirox and how the associated effects can be readily managed to ensure optimal use of this important treatment. Am. J. Hematol., 2008. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21119","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T15:51:01Z","timestamp":1196783461000},"page":"398-402","source":"Crossref","is-referenced-by-count":98,"title":["Clinical application of deferasirox: Practical patient management"],"prefix":"10.1002","volume":"83","author":[{"given":"Elliott","family":"Vichinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,12,4]]},"reference":[{"key":"e_1_2_1_2_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology\u2014v.1.2007: Myelodysplastic Syndromes. Available athttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf2007."},{"key":"e_1_2_1_3_2","volume-title":"The management of sickle cell disease","author":"National Institutes of Health NHLBI","year":"2002"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912233412607"},{"key":"e_1_2_1_5_2","first-page":"110","article-title":"Iron chelation therapy","volume":"4","author":"Hershko CM","year":"2005","journal-title":"Curr Hematol Rep"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2933"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09740-4"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2948"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3280"},{"key":"e_1_2_1_10_2","unstructured":"EMEA. Deferiprone Summary of Product Characteristics.2006. Available athttp:\/\/www.ferriprox.com."},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1867"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06455.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3430"},{"issue":"2","key":"e_1_2_1_14_2","first-page":"306","article-title":"ICL670, a once\u2010daily iron chelator, is effective and well tolerated in patients with myelodysplastic syndrome (MDS) and iron overload","volume":"90","author":"Cazzola M","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_1_15_2","first-page":"31","article-title":"Deferasirox (Exjade, ICL670) provides 24\u2010hour protection from labile plasma iron (LPI), in iron overloaded beta\u2010thalassaemia patients previously chelated with mono\u2010 or combination therapy","volume":"91","author":"Daar S","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2004.10.003"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.V106.11.2334.2334","article-title":"Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade\u00ae, ICL670) and deferoxamine (DFO)","volume":"106","author":"Vichinsky E","year":"2005","journal-title":"Blood"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.05.007"},{"issue":"2","key":"e_1_2_1_19_2","first-page":"192","article-title":"The once\u2010daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond\u2010Blackfan anaemia patients","volume":"90","author":"Tchernia G","year":"2005","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_1_20_2","first-page":"22","article-title":"Deferasirox (Exjade\u00ae, ICL670), the novel, once\u2010daily oral iron chelator, is well tolerated and effective in treating transfusional iron overload in patients with a range of rare anaemias","volume":"91","author":"Rose C","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"501a","DOI":"10.1182\/blood.V108.11.1768.1768","article-title":"Long\u2010term safety and tolerability of the once\u2010daily, oral iron chelator deferasirox (Exjade\u00ae, ICL670) in patientswith transfusional iron overload","volume":"108","author":"Cappellini MD","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_22_2","unstructured":"Exjade (deferasirox) Prescribing Information. Novartis Pharmaceuticals Corporation;2007. Available athttp:\/\/www.exjade.com."},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"32b","DOI":"10.1182\/blood.V108.11.3824.3824","article-title":"Impact on Iron removal of dose reduction for non\u2010progressive serum creatinine increases during treatment with the once\u2010daily, oral iron chelator Deferasirox (Exjade, ICL670)","volume":"108","author":"Gattermann N","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"30b","DOI":"10.1182\/blood.V108.11.3816.3816","article-title":"Summary of long\u2010term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade\u00ae, ICL670)","volume":"108","author":"Bennett W","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1988.209"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(200004)63:4<205::AID-AJH8>3.0.CO;2-8"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3180335081"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830420116"},{"issue":"1","key":"e_1_2_1_29_2","first-page":"999","article-title":"Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion\u2010dependent anaemias; a subgroup analysis","volume":"91","author":"Eleftheriou P","year":"2006","journal-title":"Haematologica"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21119","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T12:38:12Z","timestamp":1696682292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,4]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1002\/ajh.21119"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21119","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,4]]}}}